Dezhan HealthCare Co Ltd (000813) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dezhan HealthCare Co Ltd (000813) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.39 Million ≈ $-203.66K USD) by net assets (CN¥4.96 Billion ≈ $726.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 000813 net asset quality index to measure how much of total assets are equity-financed.
Dezhan HealthCare Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Dezhan HealthCare Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Dezhan HealthCare Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Dezhan HealthCare Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dezhan HealthCare Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NorthWest Healthcare Properties Real Estate Investment Trust
TO:NWH-UN
|
0.037x |
|
Retail Estates - Sicafi
BR:RET
|
0.034x |
|
Zhejiang Zuch Technology Co. Ltd. A
SHE:301280
|
N/A |
|
Shen Ma Industry Co Ltd
SHG:600810
|
0.024x |
|
Cyient Limited
NSE:CYIENT
|
0.071x |
|
Mirae Asset Daewoo Co Ltd Pref
KO:00680K
|
-0.338x |
|
Lithium Americas Corp
TO:LAC
|
-0.009x |
|
Lihuayi Weiyuan Chemical Co Ltd
SHG:600955
|
0.006x |
Annual Cash Flow Conversion Efficiency for Dezhan HealthCare Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Dezhan HealthCare Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Dezhan HealthCare Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.57 Billion ≈ $669.10 Million |
CN¥4.72 Million ≈ $691.05K |
0.001x | +136.56% |
| 2024-12-31 | CN¥5.16 Billion ≈ $755.79 Million |
CN¥-14.59 Million ≈ $-2.13 Million |
-0.003x | -111.58% |
| 2023-12-31 | CN¥5.24 Billion ≈ $766.99 Million |
CN¥127.87 Million ≈ $18.71 Million |
0.024x | -20.29% |
| 2022-12-31 | CN¥5.28 Billion ≈ $773.22 Million |
CN¥161.72 Million ≈ $23.66 Million |
0.031x | +294.75% |
| 2021-12-31 | CN¥5.47 Billion ≈ $800.43 Million |
CN¥42.41 Million ≈ $6.21 Million |
0.008x | -94.42% |
| 2020-12-31 | CN¥5.95 Billion ≈ $871.12 Million |
CN¥827.54 Million ≈ $121.09 Million |
0.139x | -49.96% |
| 2019-12-31 | CN¥5.61 Billion ≈ $821.16 Million |
CN¥1.56 Billion ≈ $228.10 Million |
0.278x | +286.30% |
| 2018-12-31 | CN¥5.28 Billion ≈ $772.85 Million |
CN¥379.78 Million ≈ $55.57 Million |
0.072x | -15.02% |
| 2017-12-31 | CN¥4.55 Billion ≈ $665.14 Million |
CN¥384.64 Million ≈ $56.28 Million |
0.085x | +21.00% |
| 2016-12-31 | CN¥3.75 Billion ≈ $548.97 Million |
CN¥262.36 Million ≈ $38.39 Million |
0.070x | -23.14% |
| 2015-12-31 | CN¥1.37 Billion ≈ $200.89 Million |
CN¥124.91 Million ≈ $18.28 Million |
0.091x | -9.86% |
| 2014-12-31 | CN¥1.35 Billion ≈ $197.84 Million |
CN¥136.47 Million ≈ $19.97 Million |
0.101x | -16.57% |
| 2013-12-31 | CN¥1.41 Billion ≈ $206.33 Million |
CN¥170.59 Million ≈ $24.96 Million |
0.121x | +204.23% |
| 2012-12-31 | CN¥415.20 Million ≈ $60.76 Million |
CN¥16.51 Million ≈ $2.42 Million |
0.040x | +197.44% |
| 2011-12-31 | CN¥428.93 Million ≈ $62.77 Million |
CN¥-17.50 Million ≈ $-2.56 Million |
-0.041x | +56.93% |
| 2010-12-31 | CN¥425.26 Million ≈ $62.23 Million |
CN¥-40.29 Million ≈ $-5.90 Million |
-0.095x | -211.41% |
| 2009-12-31 | CN¥423.61 Million ≈ $61.99 Million |
CN¥36.03 Million ≈ $5.27 Million |
0.085x | -27.99% |
| 2008-12-31 | CN¥478.64 Million ≈ $70.04 Million |
CN¥56.53 Million ≈ $8.27 Million |
0.118x | +906.90% |
| 2007-12-31 | CN¥470.05 Million ≈ $68.78 Million |
CN¥-6.88 Million ≈ $-1.01 Million |
-0.015x | -129.17% |
| 2006-12-31 | CN¥450.91 Million ≈ $65.98 Million |
CN¥22.62 Million ≈ $3.31 Million |
0.050x | -87.82% |
| 2005-12-31 | CN¥327.22 Million ≈ $47.88 Million |
CN¥134.83 Million ≈ $19.73 Million |
0.412x | +172.81% |
| 2004-12-31 | CN¥296.13 Million ≈ $43.33 Million |
CN¥44.73 Million ≈ $6.55 Million |
0.151x | +1313.82% |
| 2003-12-31 | CN¥472.51 Million ≈ $69.14 Million |
CN¥-5.88 Million ≈ $-860.37K |
-0.012x | -126.33% |
| 2002-12-31 | CN¥676.78 Million ≈ $99.03 Million |
CN¥31.98 Million ≈ $4.68 Million |
0.047x | +145.23% |
| 2001-12-31 | CN¥650.49 Million ≈ $95.19 Million |
CN¥-67.96 Million ≈ $-9.95 Million |
-0.104x | -65.03% |
| 2000-12-31 | CN¥650.09 Million ≈ $95.13 Million |
CN¥-41.16 Million ≈ $-6.02 Million |
-0.063x | -176.18% |
| 1999-12-31 | CN¥639.51 Million ≈ $93.58 Million |
CN¥53.15 Million ≈ $7.78 Million |
0.083x | -49.57% |
| 1998-12-31 | CN¥612.87 Million ≈ $89.68 Million |
CN¥101.00 Million ≈ $14.78 Million |
0.165x | -- |
About Dezhan HealthCare Co Ltd
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathi… Read more